NSCLC Clinical Trial Analysis 2026: 135+ Companies, 150+ Pipeline Therapies, 7+ Recent FDA Milestones Reshaping the Future of Lung Cancer Treatment by DelveInsight

Major NSCLC companies include BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, AbbVie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical (Pierre Fabre), Jiangsu Hengrui Medicine, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Iovance Biotherapeutics, Galecto Biotech, and others.
Non-Small Cell Lung Cancer Clinical Trial Overview

The Non-Small Cell Lung Cancer (NSCLC) development landscape remains exceptionally dynamic, with more than 135 companies advancing over 150 investigational therapies. Prominent industry participants include Daiichi Sankyo, Merck, Pfizer in collaboration with AbbVie, Eli Lilly, BioNTech, Bristol Myers Squibb, Bayer, and Innovent Biologics.

Noteworthy pipeline candidates such as trastuzumab deruxtecan, DS-1062a, pembrolizumab, domvanalimab, zimberelimab, cemiplimab, and osimertinib are demonstrating encouraging progress across multiple development phases.

Recent regulatory milestones reflect strong momentum in this space. In March 2025, Boan Biotechnology secured Orphan Drug Designation (ODD) for BA1302. During the same month, CERo Therapeutics obtained IND clearance for CER-1236. Earlier, in January 2025, Dizal's Sunvozertinib received Priority Review status, while in December 2024, Nuvation Bio's taletrectinib NDA was formally accepted for review.

Additionally, leading pharmaceutical innovators such as Merck, AstraZeneca, and Gilead continue to expand combination-based treatment strategies targeting both early-stage and metastatic NSCLC to enhance therapeutic outcomes.

DelveInsight's "Non-Small-Cell Lung Cancer Pipeline Insight 2026" delivers detailed intelligence on 135+ companies and 150+ investigational drugs shaping the NSCLC pipeline. The report evaluates both clinical and preclinical candidates and provides therapeutic segmentation based on product type, development stage, route of administration, and molecular classification. It also outlines discontinued and inactive programs within the domain.

Stay competitive in the rapidly evolving NSCLC environment by exploring in-depth company profiles, therapy assessments, and clinical advancements detailed in the comprehensive report.

Stay Ahead in the NSCLC Landscape - Explore detailed profiles of 135+ companies, 150+ pipeline therapies, trial updates, and emerging treatment strategies. Access the full [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Key Highlights from the NSCLC Pipeline Analysis

* The NSCLC pipeline reflects a highly competitive environment, with over 135 active organizations developing more than 150 novel therapies.
* Leading contributors include BridgeBio Pharma, Daiichi Sankyo, EMD Serono/Merck, AbbVie/Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical in partnership with Pierre Fabre, Jiangsu Hengrui Medicine, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Iovance Biotherapeutics, Galecto Biotech, and others.
* Prominent investigational therapies across development stages include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475), Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, and Osimertinib.

Recent Developments

* Feb 26, 2026: Zongertinib (Hernexeos) Granted accelerated approval for patients with HER2-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC).
* In September 2025, Merck (NYSE: MRK) announced U.S. FDA approval of KEYTRUDA QLEX Trademark -a subcutaneous formulation of pembrolizumab combined with berahyaluronidase alfa-for use in adults across most solid tumor indications for KEYTRUDA Registered . Developed with Alteogen Inc.'s hyaluronidase technology, KEYTRUDA QLEX must be administered by a healthcare provider and is expected to be available in the U.S. by late September.
* In August 2025, TOLREMO Therapeutics announced that its lead candidate, TT125-802, received two FDA Fast Track designations for the treatment of non-small cell lung cancer (NSCLC).
* In August 2025, Innovent Biologics received FDA clearance to begin a global Phase 3 trial (MarsLight-11) of IBI363, a novel PD-1/IL-2-bias bispecific antibody, for IO-resistant squamous NSCLC-marking its first global pivotal study.
* In August 2025, SystImmune and Bristol Myers Squibb announced that the FDA granted Breakthrough Therapy Designation to izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletions or exon 21 L858R mutations after progression on EGFR tyrosine kinase inhibitor and platinum-based chemotherapy.
* In July 2025, Thermo Fisher Scientific announced FDA approval of the Oncomine Trademark Dx Express Test on the Ion Torrent Trademark Genexus Trademark Dx Sequencer as a companion diagnostic for Dizal's ZEGFROVY Registered (sunvozertinib) to detect EGFR exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The test also supports tumor profiling of 46 genes, delivering rapid genomic insights in about 24 hours to enhance precision oncology in clinical settings.
* In June 2025, Nuvalent, Inc. (Nasdaq: NUVL) announced it will host a webcast and conference call on June 24 at 8:00 a.m. ET to discuss pivotal data for zidesamtinib, a ROS1-selective inhibitor, in TKI pre-treated advanced ROS1-positive non-small cell lung cancer from the ARROS-1 Phase 1/2 trial.
* In June 2025, Guardant Health, Inc. (Nasdaq: GH) announced that its Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the FDA. The methylation-based blood test is designed to screen for multiple cancers-including bladder, colorectal, esophageal, gastric, liver, lung, ovarian, and pancreatic-in adults aged 45+ at average risk.
* March 2025: Boan Biotechnology (06955.HK) announced FDA Orphan Drug Designation for BA1302, a CD228-targeting antibody-drug conjugate, for squamous NSCLC and pancreatic cancer.
* March 2025: CERo Therapeutics received FDA clearance for its second IND application for CER-1236, allowing initiation of a Phase I trial in advanced solid tumors, including NSCLC.
* January 2025: The FDA granted Priority Review to Dizal's NDA for Sunvozertinib aimed at advanced or metastatic NSCLC patients.
* December 2024: Nuvation Bio confirmed FDA acceptance of its NDA for taletrectinib, a next-generation ROS1 TKI for ROS1-positive advanced NSCLC.
* December 2023: Merck Sharp & Dohme initiated a Phase III study evaluating V940 combined with pembrolizumab versus placebo plus pembrolizumab in resected Stage II-IIIB NSCLC, focusing on disease-free survival outcomes.
* December 2023: AstraZeneca launched a Phase II investigation assessing perioperative regimens combining durvalumab with oleclumab, monalizumab, AZD0171, or platinum-based chemotherapy in early-stage resectable NSCLC.
* December 2023: Gilead Sciences began a Phase III study comparing zimberelimab and domvanalimab with chemotherapy versus pembrolizumab plus chemotherapy in untreated metastatic NSCLC lacking actionable genomic alterations.

Request a sample and discover the recent advances in NSCLC Treatment Drugs @ [https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

NSCLC Disease Overview

Non-Small Cell Lung Cancer accounts for nearly 85% of all lung cancer diagnoses globally. Compared to small cell lung cancer, NSCLC typically progresses more gradually, enabling broader therapeutic intervention opportunities.

Common symptoms include chronic cough, chest discomfort, breathing difficulty, and unexplained weight loss. Diagnosis often involves imaging modalities such as CT scans, tissue biopsies, and molecular profiling to detect actionable mutations.

Staging spans from Stage I (localized disease) to Stage IV (metastatic spread), significantly influencing treatment strategies.

Therapeutic approaches encompass surgery, radiation, chemotherapy, targeted agents, and immunotherapies. Precision therapies targeting EGFR, ALK, and ROS1 mutations have transformed individualized care, while immune checkpoint inhibitors have substantially improved survival metrics.

Ongoing clinical research continues to evaluate next-generation agents and combination regimens aimed at optimizing survival outcomes. Prognosis varies depending on disease stage, molecular characteristics, and patient health status, with early detection remaining critical.

Find out more about NSCLC Treatment Landscape @ [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Emerging Drug Profiles

V940 - Merck Sharp & Dohme LLC An mRNA-based personalized vaccine engineered to stimulate T-cell responses against tumor-specific neoantigens. Currently progressing through Phase III evaluation in NSCLC.

QL1706 - Qilu Pharmaceutical Co., Ltd. A bifunctional antibody targeting both PD-1 and CTLA-4 pathways to amplify immune-mediated tumor suppression. It is under Phase III investigation.

Zenocutuzumab (MCLA-128) - Merus N.V. A bispecific antibody that disrupts HER2-HER3 signaling in NRG1 fusion-positive tumors. Presently in Phase II development.

ZW49 - Zymeworks BC Inc. A HER2-directed bispecific antibody-drug conjugate delivering cytotoxic payloads while inhibiting HER2 signaling. It is in early Phase I studies.

Therapeutic Assessment of the NSCLC Pipeline

Approximately 135 companies are actively advancing NSCLC drug candidates, with Daiichi Sankyo among those leading Phase III programs.

The report evaluates more than 150 products across:

* Phase III (Late-stage)
* Phase II (Mid-stage)
* Phase I (Early-stage)
* Preclinical and Discovery phases
* Discontinued or inactive programs

Route of Administration (ROA) Categories

Pipeline therapies are segmented into:

* Subcutaneous
* Intravenous
* Oral
* Parenteral
* Intramuscular

Molecule Type Classification

NSCLC drug candidates are categorized into:

* Small molecules
* Peptides
* Polymers
* Gene therapies
* Monoclonal antibodies

Learn more about the emerging NSCLC Pipeline Therapies @ [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

NSCLC Market Drivers

* Significant Disease Burden: Representing roughly 85% of lung cancer cases, NSCLC drives sustained treatment demand.
* Advancement in Precision Medicine: Expansion of therapies targeting EGFR, ALK, ROS1, KRAS, and PD-1/PD-L1 mutations.
* Immunotherapy Revolution: Agents such as pembrolizumab, cemiplimab, and durvalumab have reshaped clinical outcomes.
* Extensive R&D Pipeline: Over 150 investigational therapies incorporating innovative modalities including antibody-drug conjugates and next-generation TKIs.
* Regulatory Acceleration: FDA priority reviews, orphan drug designations, and breakthrough statuses streamline development.
* Enhanced Diagnostics: Biomarker-driven strategies, including PD-L1 testing and NGS panels, improve patient stratification.

NSCLC Market Barriers

* Elevated treatment costs for targeted and immunotherapeutic agents.
* Emergence of resistance to targeted inhibitors.
* Molecular heterogeneity complicating personalized treatment.
* Accessibility challenges in emerging economies.
* Safety concerns and immune-related adverse events.
* Clinical trial complexities and regulatory constraints.

Scope of the Non-Small Cell Lung Cancer Pipeline Report

* Coverage- Global
* NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* NSCLC Companies- BridgeBio Pharma (NASDAQ: BBIO), Daiichi Sankyo (TYO: 4568), EMD Serono/Merck (FWB: MRK), AbbVie (NYSE: ABBV)/Pfizer (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), BioNTech SE (NASDAQ: BNTX), Shenzhen TargetRx (Private), Taiho Pharmaceutical (Private), Chong Kun Dang (KRX: 185750), Bristol Myers Squibb (NYSE: BMY), Innovent Biologics (HKEX: 01801), Xuanzhu Biopharmaceutical (Private), Bayer (FWB: BAYN), GeneScience Pharmaceuticals (Private), InventisBio (SHA: 688382), Apollomics (NASDAQ: APLM), Imugene (ASX: IMU), Ono Pharmaceutical (TYO: 4528)/Pierre Fabre (Private), Jiangsu Hengrui Medicine Co. (SHA: 600276), Surface Oncology (acquired by Coherus BioSciences, NASDAQ: CHRS), Inhibrx (NASDAQ: INBX), Sinocelltech (SHA: 688520), Mirati Therapeutics (NASDAQ: MRTX), REVOLUTION Medicines (NASDAQ: RVMD), Yong Shun Technology Development (Private), Iovance Biotherapeutics (NASDAQ: IOVA), Galecto Biotech (NASDAQ: GLTO), and others.
* NSCLC Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.

Dive deep into rich insights for new drugs for NSCLC treatment, Visit @ NSCLC Market Drivers and Barriers, and Future Perspective [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

* Introduction
* Executive Summary
* NSCLC Disease Overview (Etiology, Pathophysiology, Diagnosis, Treatment)
* Pipeline Comparative Analysis
* Therapeutic Segmentation by Stage, ROA, and Molecule Type
* Analytical Insights and Expert Perspectives
* Detailed Drug Profiles (Phase III, II, I, Preclinical)
* Key Companies and Products
* Unmet Needs
* Market Drivers and Challenges
* Future Outlook and Conclusion
* Appendix

About DelveInsight

DelveInsight is a specialized healthcare consulting and market research organization dedicated to the life sciences sector. The firm delivers strategic intelligence and end-to-end analytical solutions to pharmaceutical companies, supporting informed decision-making and performance enhancement across global markets.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nsclc-clinical-trial-analysis-2026-135-companies-150-pipeline-therapies-7-recent-fda-milestones-reshaping-the-future-of-lung-cancer-treatment-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.